The American Journal of Managed Care2d
For Obesity and HFpEF, Tirzepatide Cuts Risk of CV Death or Worsening HF by 38%
Payers and employers have tightened access to the glucagon-like peptide-1 receptor agonist class once these therapies became ...
FiercePharma4d
Lilly unwraps detailed data showing tirzepatide kept nearly 99% of prediabetic patients diabetes-free over 3 years
Following an impressive data drop this summer highlighting the potential for Eli Lilly’s tirzepatide to stave off progression ...
Monthly Prescribing Reference3d
Long-Term Tirzepatide Treatment Reduces Weight and Diabetes Progression Risk
The detailed results were published in The New England Journal of Medicine and were presented at ObesityWeek 2024.
Medscape12d
FDA Updates GLP-1 Label With Pulmonary Aspiration Warning
Victoza); and the dual glucose-dependent insulinotropic polypeptide (GIP)/GLP-1 tirzepatide (Mounjaro, Zepbound). “This was a safety-related labeling change for the glucagon-like peptide 1 receptor ...